Back to search

University of Sheffield

How do transcribed enhancers confer genetic risk in Amyotrophic Lateral Sclerosis?

Abstract

dc:description.abstract

Spatial interactions between transcriptional regulatory elements establish gene regulatory networks. Enhancers are fundamental to such regulatory networks, conferring precise spatiotemporal gene expression patterns. Thus, it is not surprising that variation within enhancers may underpin the genetic architecture of disease. In fact, the vast majority of single nucleotide polymorphisms (SNPs) associated with human complex diseases map to the non-coding genome, with causal disease variants particularly enriched within enhancers. The transcription of enhancer RNAs (eRNAs), the non-coding RNA species encoded from active enhancers, is a key factor contributing to enhancer activity. Not only may enhancer transcription data provide insight into how enhancer activity changes upon mutation, but enhancers containing disease-associated variants may yield aberrant eRNAs capable of disrupting transcriptional regulation to culminate in disease phenotype. By mapping putative Amyotrophic Lateral Sclerosis (ALS)-associated enhancers, we evaluate their activity by assessing chromatin accessibility, enhancer-associated chromatin modifications, and eRNA transcription, in the context of disease. By employing epigenomic and transcriptomic analyses, coupled with reporter assays to assess the impact of ALS-associated SNPs, we gain insights into the transcriptional and regulatory consequences of disease-associated SNPs on enhancer function. Using computational RNA structure prediction, enhancers containing ALS-associated variants are predicted to yield eRNAs with altered structure, and therefore potentially function. In disease contexts, we further explore how both distal and intragenic ALS-associated enhancers affect not only gene expression but differential messenger RNA (mRNA) isoform expression. Therefore, investigating the effects of ALS-associated SNPs on enhancer activity, eRNA expression and eRNA structure not only provide great insights into the pathogenic mechanisms underlying sporadic ALS, but may also contribute to a broader understanding of how eRNAs function independently from their associated enhancers.

Degree

thesis:*
Name dc:type.qualificationname
Ph.D
Level dc:type.qualificationlevel
doctoral
Grantor dc:publisher.institution
University of Sheffield
Year dc:date.issued
2024

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Harrison, Laura Jane
Advisors dc:contributor.advisor
  • Bose, Daniel
  • Cooper-Knock, Johnathan
ORCID person:identifier.orcid

Rights

Language dc:language.dcterms_iso639_2
eng

Identifiers

dc:identifier.*
Dc Identifier Grantnumber
DiMeN Doctoral Training Partnership

Chain of custody

source
Harvested from
White Rose University Consortium
Base URL
etheses.whiterose.ac.uk/cgi/oai2
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
related terms
citation

Harrison, Laura Jane. How do transcribed enhancers confer genetic risk in Amyotrophic Lateral Sclerosis?. doctoral thesis, University of Sheffield, 2024.